RBX2660

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

RBX2660 as stool-derived enema formulation is developed by Rebiotix Inc.
Garber 2020 Nat. Rev. Drug Discov. 19: 655–656
Gawey & Khanna 2023 Gastroenterol Hepatol (N Y) 19(6): 319-328

Fecal microbiota RBX2660 is the ﬁrst single-dose, microbiota-based live biotherapeutic product (LBP) approved by the US Food and Drug Administration (FDA) for the prevention of recurrence of CDI in adults, following antibiotic treatment for [Clostridioides difficile infection (CDI) (recurrent)](brain://fFktMkSuWkmPdI87MW3ShQ/Clostri…

References (Sources)

Clostridioides difficile Infection: Landscape and Microbiome Therapeutics
Gawey & Khanna 2023 Gastroenterol Hepatol (N Y) 19(6): 319-328
Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3
Feuerstadt et al. 2024 J Clin Gastroenterol 58(8): 818-824
First microbiome-based drug clears phase III, in clinical trial turnaround
Garber 2020 Nat. Rev. Drug Discov. 19: 655–656
Update on microbiota-derived therapies for recurrent Clostridioides difficile infections
Benech et al. 2024 Clinical Microbiology and Infection 30: 462-468
Review

AI Chat

11/5/2026

Chat with our artificial intelligence:

Start chat!

RBX2660

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat